Literature DB >> 22129796

Predictors of nonalcoholic steatohepatitis in obese children.

Stacee Marie Lerret1, Laura Garcia-Rodriguez, Joseph Skelton, Vincent Biank, Denise Kilway, Grzegorz Telega.   

Abstract

As the prevalence of childhood obesity increases, the incidence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH) also escalates. This study's purpose was to identify the clinical criteria to aid in determining when a liver biopsy is indicated for this growing population because currently no guidelines exist. We performed a retrospective chart review on all patients who were seen in the Nutrition Exercise and Weight Loss Kids™ Program at the Children's Hospital of Wisconsin from July 2003 through December 2004. We analyzed only individuals who underwent liver biopsy with the following criteria: (1) no evidence of other liver disease and (2) aspartate transaminase or alanine aminotransferase greater than 200 IU/L or any elevation of or for more than 6 months. Of the 284 patients reviewed, only eight patients (3%) met the criteria for analysis. Biopsy results demonstrated that 100% had histological evidence of NASH with steatosis, and seven of the eight (87.5%) had NASH with fibrosis, cirrhosis, or both. Obese children with an aspartate transaminase or alanine aminotransferase greater than 200 IU/L or any elevation of aspartate transaminase or alanine aminotransferase for more than 6 months, have a strong likelihood of having NASH with or without fibrosis, cirrhosis, or both.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129796      PMCID: PMC3977472          DOI: 10.1097/SGA.0b013e3182371356

Source DB:  PubMed          Journal:  Gastroenterol Nurs        ISSN: 1042-895X            Impact factor:   0.978


  12 in total

Review 1.  Evaluation and management of non-alcoholic steatohepatitis.

Authors:  Seela Ramesh; Arun J Sanyal
Journal:  J Hepatol       Date:  2004-12-30       Impact factor: 25.083

2.  Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis.

Authors:  Angelo Iacobellis; Matilde Marcellini; Angelo Andriulli; Francesco Perri; Gioacchino Leandro; Rita Devito; Valerio Nobili
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

3.  Liver biopsy: the best, not the gold standard.

Authors:  Pierre Bedossa; Fabrice Carrat
Journal:  J Hepatol       Date:  2008-11-06       Impact factor: 25.083

Review 4.  Pediatric nonalcoholic fatty liver disease in 2009.

Authors:  Anna Alisi; Melania Manco; Andrea Vania; Valerio Nobili
Journal:  J Pediatr       Date:  2009-10       Impact factor: 4.406

Review 5.  Pediatric obesity: etiology and treatment.

Authors:  Melissa K Crocker; Jack A Yanovski
Journal:  Endocrinol Metab Clin North Am       Date:  2009-09       Impact factor: 4.741

Review 6.  Diagnosis and epidemiology of cirrhosis.

Authors:  Harvey B Lefton; Anthony Rosa; Matthew Cohen
Journal:  Med Clin North Am       Date:  2009-07       Impact factor: 5.456

Review 7.  Histopathology of non-alcoholic fatty liver disease.

Authors:  Elizabeth M Brunt
Journal:  Clin Liver Dis       Date:  2009-11       Impact factor: 6.126

Review 8.  Lifestyle modification as the primary treatment of NASH.

Authors:  Brent A Neuschwander-Tetri
Journal:  Clin Liver Dis       Date:  2009-11       Impact factor: 6.126

9.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

Authors:  J Ludwig; T R Viggiano; D B McGill; B J Oh
Journal:  Mayo Clin Proc       Date:  1980-07       Impact factor: 7.616

Review 10.  Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease.

Authors:  Leon A Adams; Paul Angulo
Journal:  Clin Liver Dis       Date:  2007-02       Impact factor: 6.126

View more
  6 in total

1.  Detection of carcinogenic etheno-DNA adducts in children and adolescents with non-alcoholic steatohepatitis (NASH).

Authors:  Ulrike Teufel; Teresa Peccerella; Guido Engelmann; Thomas Bruckner; Christa Flechtenmacher; Gunda Millonig; Felix Stickel; Georg F Hoffmann; Peter Schirmacher; Sebastian Mueller; Helmut Bartsch; Helmut K Seitz
Journal:  Hepatobiliary Surg Nutr       Date:  2015-12       Impact factor: 7.293

Review 2.  The role of reactive oxygen species (ROS) and cytochrome P-450 2E1 in the generation of carcinogenic etheno-DNA adducts.

Authors:  Kirsten Linhart; Helmut Bartsch; Helmut K Seitz
Journal:  Redox Biol       Date:  2014-09-06       Impact factor: 11.799

Review 3.  Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis.

Authors:  Akifumi Kushiyama; Yusuke Nakatsu; Yasuka Matsunaga; Takeshi Yamamotoya; Keiichi Mori; Koji Ueda; Yuki Inoue; Hideyuki Sakoda; Midori Fujishiro; Hiraku Ono; Tomoichiro Asano
Journal:  Mediators Inflamm       Date:  2016-12-14       Impact factor: 4.711

Review 4.  Amidst the COVID-19 pandemic childhood obesity is still an epidemic-spotlight on obesity's multifactorial determinants.

Authors:  Katya Saliba; Sarah Cuschieri
Journal:  Health Sci Rev (Oxf)       Date:  2021-12-03

5.  Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease.

Authors:  Katharina Maruszczak; Konrad Radzikowski; Sebastian Schütz; Harald Mangge; Peter Bergsten; Anders Forslund; Hannes Manell; Thomas Pixner; Håkan Ahlström; Joel Kullberg; Katharina Mörwald; Daniel Weghuber
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-05       Impact factor: 6.055

Review 6.  A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence.

Authors:  Jonathan L Temple; Paul Cordero; Jiawei Li; Vi Nguyen; Jude A Oben
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.